- Home
- FORM vs CELC Comparison
FORM vs CELC Comparison
Compare FORM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORM
- CELC
- Stock Information
- Founded
- FORM 1993
- CELC 2011
- Country
- FORM United States
- CELC United States
- Employees
- FORM N/A
- CELC N/A
- Industry
- FORM Semiconductors
- CELC Medical Specialities
- Sector
- FORM Technology
- CELC Health Care
- Exchange
- FORM Nasdaq
- CELC Nasdaq
- Market Cap
- FORM 2.7B
- CELC 2.3B
- IPO Year
- FORM N/A
- CELC 2017
- Fundamental
- Price
- FORM $39.69
- CELC $50.51
- Analyst Decision
- FORM Buy
- CELC Strong Buy
- Analyst Count
- FORM 8
- CELC 6
- Target Price
- FORM $38.14
- CELC $63.00
- AVG Volume (30 Days)
- FORM 942.8K
- CELC 1.0M
- Earning Date
- FORM 10-29-2025
- CELC 11-13-2025
- Dividend Yield
- FORM N/A
- CELC N/A
- EPS Growth
- FORM N/A
- CELC N/A
- EPS
- FORM 0.57
- CELC N/A
- Revenue
- FORM $764,554,000.00
- CELC N/A
- Revenue This Year
- FORM $2.58
- CELC N/A
- Revenue Next Year
- FORM $7.33
- CELC N/A
- P/E Ratio
- FORM $69.83
- CELC N/A
- Revenue Growth
- FORM 8.30
- CELC N/A
- 52 Week Low
- FORM $22.58
- CELC $7.58
- 52 Week High
- FORM $50.79
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- FORM 74.52
- CELC 49.45
- Support Level
- FORM $34.80
- CELC $44.42
- Resistance Level
- FORM $40.86
- CELC $52.76
- Average True Range (ATR)
- FORM 1.51
- CELC 3.10
- MACD
- FORM 0.50
- CELC -1.11
- Stochastic Oscillator
- FORM 88.07
- CELC 51.39
About FORM FormFactor Inc. FormFactor Inc.
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.